June 29, 2026 03:25 am (IST)
Migraine treatment injection from Dr Reddy's Lab now available in the US
Hyderabad/Princeton-NJ, Apr 19 (IBNS) Promius Pharma LLC, a subsidiary of Dr. Reddy's Laboratories Ltd, has informed on Tuesday that its ZEMBRACE SymTouch (sumatriptan injection) 3 mg, which was approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the U.S.
The company said that ZEMBRACE SymTouch is a pre filled, low-dose, ready-to-use, 2-step autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. Because ZEMBRACE SymTouch is a subcutaneous injection, it may lead to rapid relief of migraine.
Migraineurs often have more than one kind of attack. Different types of medications can be used to treat different types of attacks.
According to Roger Cady, MD, Associate Executive Chairman of the National Headache Foundation “ZEMBRACE SymTouch is a welcome addition to the toolkit for acute treatment of migraine. This 3-mg, easy to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks. Also, the 3-mg dose allows for up to 4 doses of ZEMBRACE SymTouch in a 24-hour period, thus allowing dosing flexibility for patients.”
ZEMBRACE SymTouch is available as a box of 4 autoinjectors.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Best Car Insurance for Cars Driven Less Than 5,000 KM a Year
Sat, Jun 27 2026
Will pre-2005 Rs.10, Rs. 20, Rs. 50 and Rs. 100 notes become invalid after June 30? Here's the truth
Sat, Jun 27 2026
From Kolkata to corporate America: How Shankh Mitra became the world's second-highest paid CEO
Fri, Jun 26 2026
TVS unveils fresh NTORQ lineup with bold new features and styling
Fri, Jun 26 2026
Amazon's massive India bet! Andy Jassy announces $48 billion investment after meeting PM Modi
Thu, Jun 25 2026
Rajesh Exports crashes 5%! ED probe triggers fresh investor panic
Thu, Jun 25 2026
